This company listing is no longer active
RD8 Stock Overview
Processes, manufactures, sells, and distributes cannabis materials in Canada and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Radient Technologies Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.0005 |
| 52 Week High | CA$0.021 |
| 52 Week Low | CA$0.0005 |
| Beta | 0.88 |
| 11 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -97.56% |
| 33 Year Change | -99.44% |
| 5 Year Change | -99.95% |
| Change since IPO | -99.83% |
Recent News & Updates
Recent updates
Shareholder Returns
| RD8 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.2% | 0.9% |
| 1Y | -97.6% | -17.5% | 5.7% |
Return vs Industry: RD8 underperformed the German Pharmaceuticals industry which returned -11.5% over the past year.
Return vs Market: RD8 underperformed the German Market which returned -7.8% over the past year.
Price Volatility
| RD8 volatility | |
|---|---|
| RD8 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 4.7% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: RD8's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine RD8's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | n/a | Steven Splinter | www.radientinc.com |
Radient Technologies Inc., together with its subsidiaries, processes, manufactures, sells, and distributes cannabis materials in Canada and internationally. It offers vape cartridges or dabs, cannabis oil, standardized cannabinoid ingredients, cannabis extracts, and cannabis formulations. The company also provides extraction services for the extraction, purification, and isolation of cannabinoids for third parties.
Radient Technologies Inc. Fundamentals Summary
| RD8 fundamental statistics | |
|---|---|
| Market cap | €1.88m |
| Earnings (TTM) | -€7.86m |
| Revenue (TTM) | €2.19m |
0.9x
P/S Ratio-0.2x
P/E RatioIs RD8 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RD8 income statement (TTM) | |
|---|---|
| Revenue | CA$3.15m |
| Cost of Revenue | CA$3.87m |
| Gross Profit | -CA$718.42k |
| Other Expenses | CA$10.58m |
| Earnings | -CA$11.30m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.021 |
| Gross Margin | -22.82% |
| Net Profit Margin | -359.00% |
| Debt/Equity Ratio | -80.4% |
How did RD8 perform over the long term?
See historical performance and comparison